Venture capital fund
Every published round MRCF BTF (MRCF4) took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies MRCF BTF (MRCF4) has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for MRCF BTF (MRCF4), as distinct from the investments it has made.
Companies MRCF BTF (MRCF4) has backed that another company then bought. An exit for the holding, not a deal MRCF BTF (MRCF4) did.
Stories naming MRCF BTF (MRCF4). Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brandon Capital's Medical Research Commercialisation Fund has launched its fifth vehicle, MRCF5, completing a NZ$224 million first close and targeting NZ$267 million, while recalling earlier portfolio exits of Elastagen, Spinifex and Fibrotech.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Startup Daily